DRTP: Effectiveness of a Developmental Reciprocity Treatment Program in Autism

Sponsor
Stanford University (Other)
Overall Status
Suspended
CT.gov ID
NCT03131635
Collaborator
(none)
52
1
2
66.2
0.8

Study Details

Study Description

Brief Summary

This is a research study examining the effectiveness of a Developmental Reciprocity Treatment Program (DRT-P) in treating social deficits in children with Autism Spectrum Disorders (ASD). Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.

Researchers have begun to develop strategies to investigate the effectiveness of combining a parent training program teaching parents how to implement DRP with in-home, therapist-implemented treatment. To determine the effectiveness of the DRT-P, it will be compared to a delayed treatment group (DTG) by conducting a randomized controlled 24-week trial. This research will allow us to help in the development of therapeutic approaches that can meet the increasing service demands for families. We hope that investigating interventions that aim to improve core deficits will aid in providing better care for children with autism.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Developmental Reciprocity Treatment Program (DRT-P)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of a Developmental Reciprocity Treatment Program in Autism
Actual Study Start Date :
Jul 26, 2017
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Developmental Reciprocity Treatment Program (DRT-P)

Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.

Behavioral: Developmental Reciprocity Treatment Program (DRT-P)
Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.

No Intervention: Delayed Treatment Group (DTG)

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline on the Social Responsiveness Scale (SRS) at 6, 12, and 24 weeks [Baseline, 6, 12, and 24 weeks]

  2. Change from Baseline on the Brief Observation of Social Communication Change (BOSCC) at 24 weeks [Baseline and 24 weeks]

Secondary Outcome Measures

  1. Change from Baseline on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  2. Change from Baseline on the Stanford Social Dimensions Scale (SSDS) Questionnaire. [Baseline, 12, and 24 weeks]

Other Outcome Measures

  1. Change from Baseline on the Structured Lab Observation (SLO) at 6, 12, and 24 weeks [Baseline, 6, 12, and 24 weeks]

  2. Change from Baseline on the Mullen Scales of Early Learning at 24 weeks [Baseline and 24 weeks]

  3. Change from Baseline on the MacArthur-Bates Communication Development Inventory at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  4. Change from Baseline on the Behavior Rating Inventory of Executive Function, Preschool (BRIEF-P) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  5. Change from Baseline on the Clinical Global Impression Scale at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  6. Change from Baseline on the Family Empowerment Scale (FES) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  7. Change from Baseline on the Social attention and word-learning eye tracking task at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  8. Change from Baseline on the Short Sensory Profile Questionnaire (SSPQ) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  9. Change from Baseline on the Parenting Stress Index (PSI) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  10. Change from Baseline on the Aberrant Behavior Checklist (ABC) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  11. Change from Baseline on the Repetitive Behavior Scale Revised (RBS-R) at 12, and 24 weeks [Baseline, 12, and 24 weeks]

  12. Change from Baseline on the Pediatric Quality of Life Scale at 12, and 24 weeks [Baseline, 12, and 24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Autism Spectrum Disorder based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule (ADOS-2), DSM-5, and expert clinical opinion;

  • Males and females in good medical health between 2.0 and 5 years 11 months;

  • Ability to participate in the testing procedures to the extent that valid standard scores can be obtained;

  • Stable treatment (e.g., applied behavior analysis), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation;

  • Availability of at least one English-speaking parent who can consistently participate in parent training and research measures;

  • Clinical Global Impression(CGI) Severity Social Interaction and Communication Integrated Subscale ≥4;

  • Meet the cutoff for Autism on the ADOS-2.

Exclusion Criteria:
  • Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.);

  • A well-established genetic syndrome, such as Fragile X;

  • Presence of active medical problem (e.g., unstable seizure disorder or heart disease);

  • Child's primary language other than English;

  • Previous adequate trial or training of a developmentally based intervention;

  • Participants living more than 45 miles from Stanford University;

  • Children with more than 20 hours of in-home ABA;

  • At least one room of the house must be available to be dedicated to treatment during session times;

  • There must be no serious health and safety risks present in the home environment;

  • The research team has the right to refuse to perform sessions in-home even if the criteria above are met.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University Stanford California United States 94305-5719

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Antonio Y. Hardan, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Hardan, Professor of Psychiatry and Behavioral Sciences, Stanford University
ClinicalTrials.gov Identifier:
NCT03131635
Other Study ID Numbers:
  • IRB 40026
First Posted:
Apr 27, 2017
Last Update Posted:
Feb 16, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Antonio Hardan, Professor of Psychiatry and Behavioral Sciences, Stanford University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2022